HOT TOPICS - ANNEXA-I Trial Neurocritical Care Society podcast

Artwork

Criticalcare Neurocriticalcare Fitness Neurocritical Care Society Education Neurocritical Care Neurology Science Medicine

Indhold leveret af Education Neurocritical Care and Neurocritical Care Society. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Education Neurocritical Care and Neurocritical Care Society eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Neurocritical Care Society Podcast « »
HOT TOPICS - ANNEXA-I Trial

12d ago 1:01:20

Del

MP4•Episode hjem

Indhold leveret af Education Neurocritical Care and Neurocritical Care Society. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Education Neurocritical Care and Neurocritical Care Society eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion had not been well studied, until the ANNEXA-I Trial. To discuss this week's Hot Topic, Nicholas Morris, MD is joined by one of the trial's collaborators, Ashkan Shoamanesh, MD as well as clincial pharmacist Andrew Webb, PharmD, BCCCP.

Listeners can also join the NCS Journal Club which will be discussing the ANNEXA-I Trial on "X" / Twitter on Tuesday, July 16th starting at 9am CT.

… continue reading

102 episoder

#Criticalcare #Neurocriticalcare #Fitness #Neurocritical Care Society #Education Neurocritical Care #Neurology #Science #Medicine

Artwork

HOT TOPICS - ANNEXA-I Trial

Neurocritical Care Society Podcast

85 subscribers

published 12d ago

Del

MP4•Episode hjem

Indhold leveret af Education Neurocritical Care and Neurocritical Care Society. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Education Neurocritical Care and Neurocritical Care Society eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion had not been well studied, until the ANNEXA-I Trial. To discuss this week's Hot Topic, Nicholas Morris, MD is joined by one of the trial's collaborators, Ashkan Shoamanesh, MD as well as clincial pharmacist Andrew Webb, PharmD, BCCCP.

Listeners can also join the NCS Journal Club which will be discussing the ANNEXA-I Trial on "X" / Twitter on Tuesday, July 16th starting at 9am CT.

… continue reading

102 episoder

#Criticalcare #Neurocriticalcare #Fitness #Neurocritical Care Society #Education Neurocritical Care #Neurology #Science #Medicine

كل الحلقات

×

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

Lyt til 500+ emner